Detalle Publicación

ARTÍCULO
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Autores: Chari, A.; Samur, M. K.; Martínez-López, J.; Cook, G.; Biran, N.; Yong, K.; Hungria, V.; Engelhardt, M.; Gay, F.; Feria, A. G.; Oliva, S.; Oostvogels, R.; Gozzetti, A.; Rosenbaum, C.; Kumar, S.; Stadtmauer, E. A.; Einsele, H.; Beksac, M.; Weisel, K.; Anderson, K. C.; Mateos, M. V.; Moreau, P.; San Miguel Izquierdo, Jesús; Munshi, N. C.; Avet-Loiseau, H. (Autor de correspondencia)
Título de la revista: BLOOD
ISSN: 0006-4971
Volumen: 136
Número: 26
Páginas: 3033 - 3040
Fecha de publicación: 2020
Lugar: WOS
Resumen:
The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19-infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.